Does TACROLIMUS Cause Malignant neoplasm progression? 110 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 110 reports of Malignant neoplasm progression have been filed in association with TACROLIMUS (Tacrolimus). This represents 0.1% of all adverse event reports for TACROLIMUS.
110
Reports of Malignant neoplasm progression with TACROLIMUS
0.1%
of all TACROLIMUS reports
46
Deaths
20
Hospitalizations
How Dangerous Is Malignant neoplasm progression From TACROLIMUS?
Of the 110 reports, 46 (41.8%) resulted in death, 20 (18.2%) required hospitalization, and 8 (7.3%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TACROLIMUS. However, 110 reports have been filed with the FAERS database.
What Other Side Effects Does TACROLIMUS Cause?
Off label use (8,718)
Drug ineffective (6,214)
Product use in unapproved indication (5,057)
Acute kidney injury (4,005)
Transplant rejection (3,526)
Cytomegalovirus infection (3,320)
Covid-19 (3,201)
Drug interaction (2,896)
Diarrhoea (2,854)
Toxicity to various agents (2,845)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which TACROLIMUS Alternatives Have Lower Malignant neoplasm progression Risk?
TACROLIMUS vs TACROLIMUS\TACROLIMUS ANHYDROUS
TACROLIMUS vs TADALAFIL
TACROLIMUS vs TAFAMIDIS
TACROLIMUS vs TAFAMIDIS MEGLUMINE
TACROLIMUS vs TAFASITAMAB